Phase II study of fulvestrant 250mg/month in patients with recurrent or metastatic endometrial cancer: A study of the Arbeitsgemeinschaft Gynäkologische Onkologie-Reference-Cited by-同舟云学术

Phase II study of fulvestrant 250mg/month in patients with recurrent or metastatic endometrial cancer: A study of the Arbeitsgemeinschaft Gynäkologische Onkologie

Published:2013-06 Issue:3 Volume:129 Page:495-499
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Emons Günter,Günthert Andreas,Thiel Falk C.,Camara Oumar,Strauss Hans-Georg,Breitbach Georg-Peter,Kölbl Heinz,Reimer Toralf,Finas Dominique,Rensing Klaus

Funder

Astra Zeneca Germany

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference21 articles.

1. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration;Humber;Ann Oncol,2007

2. Current treatment of metastatic endometrial cancer;Temkin;Cancer Control,2009

3. Systematic review of systemic therapy for advanced or recurrent endometrial cancer;Carey;Gynecol Oncol,2006

4. Hormonal therapy in advanced or recurrent endometrial cancer;Kokka;Cochrane Database Syst Rev,2010

5. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study;Thigpen;J Clin Oncol,2001

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study);International Journal of Gynecologic Cancer;2024-05-09

2. Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?;International Journal of Gynecologic Cancer;2023-08-27

3. Evolution of systemic therapy for disseminated endometrial cancer: literature review;Malignant tumours;2023-06-21

4. Do Not Forget about Hormonal Therapy for Recurrent Endometrial Cancer: A Review of Options, Updates, and New Combinations;Cancers;2023-03-16

5. Invasiveness of endometrial cancer cell lines is potentiated by estradiol and blocked by a traditional medicine Guizhi Fuling at clinically relevant doses;Frontiers in Oncology;2023-01-16